Ospedale S. Eugenio
- Address
- lock Available on a paid plan
Immune System Diseases
The U.O.C. Ematologia at Ospedale S. Eugenio is advancing research in immune system diseases, concentrating on innovative treatments for advanced malignancies and immune‑mediated conditions.
- Evaluation of parsaclisib as a single agent and in combination with other targeted therapies
- Safety monitoring for long‑term use of novel oral inhibitors
- Exploration of synergistic effects with itacitinib, ruxolitinib, or ibrutinib
These studies aim to improve therapeutic options for patients with refractory blood cancers, offering continued access to promising drugs while gathering essential safety data.
Neoplasms
Research at the site targets neoplasms, specifically follicular lymphoma and marginal zone lymphoma, assessing new antibody‑based regimens to boost response rates in relapsed or refractory cases.
- Combination of tafasitamab, lenalidomide, and rituximab versus standard therapy
- Comparison of efficacy outcomes in relapsed/refractory lymphoma patients
- Investigation of patient‑centered benefits such as progression‑free survival
The goal is to determine whether the novel immunotherapy improves disease control and quality of life for individuals who have exhausted prior treatments.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Incyte Corp.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ospedale S. Eugenio
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, versus Standard of Care Therapy in Participants with Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma (OLYMPIA-4) | Regeneron Pharmaceuticals Inc. | Phase III | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 22 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 2 | Unknown | 2021-06-05 | 2024-02-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.